Search Results

Calder Biosciences Inc., today announced a clinical supply agreement with Biodextris Inc.

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced it has entered into a material transfer agreement with Biodextris Inc. for the use of three intranasal mucosal adjuvants in the Company’s Terra CoV-2 vaccine against COVID-19. Adjuvants are added to vaccines to enhance their immunogenicity. BDX100, BDX300 and BDX301 are proteosome-based adjuvants comprised of proteins and lipopolysaccharides

I-Mab Biopharma and Jiangsu Nhwa Pharmaceutical announce on April 5th , 2019 that they have entered into collaborative research agreement with world-renowned scientists and clinicians at the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital and Biodextris, a Montreal-based biologics contract development and manufacturing organization, to jointly develop a novel immuno-stimulatory therapy for neurologic disorders by harnessing the natural power of the immune system.

I-Mab (the “Company”) (Nasdaq: IMAB), today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) submission for Protollin, an investigational drug to treat Alzheimer’s disease, enabling a Phase 1 clinical trial to be initiated.

I-Mab today announced that the first patient had been dosed in the I-Mab and Nhwa-sponsored U.S. Phase I study of Protollin, an investigational drug being co-developed to treat Alzheimer’s disease.

Oragenics, Inc. today announced that the Company has entered into an exclusive global license agreement with Inspirevax Inc. for its novel intranasal mucosal adjuvant, BDX301.

Executive Chairman Affirms Company Direction with Commitment to Speedy Execution of Business Strategy Highlights Deep Bench Strength Among Management, Board and Advisors in Vaccine Development and in Life Sciences

Oragenics, Inc. announced it has entered into a licensing agreement with the National Research Council of Canada that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants.